This protocol applies to patients with definite antiphospholipid syndrome (APS) who have had a first unprovoked venous thrombosis. In this setting, vitamin K antagonist therapy is recommended, and long-term anticoagulation is indicated.
DOI: 10.1136/annrheumdis-2019-215213
In patients with definite APS and first venous thrombosis: A. Treatment with VKA with a target INR 2–3 is recommended.
In patients with unprovoked first venous thrombosis, anticoagulation should be continued long term.
If the target INR of 2–3 had been achieved, addition of LDA, increase of INR target to 3–4 or change to LMWH may be considered.
View source ↗